Doxorubicin-induced thymus senescence

Rukhsana Sultana, Fabio Di Domenico, Michael Tseng, Jian Cai, Teresa Noel, R. Lakshman Chelvarajan, William D. Pierce, Ciara Cini, Subbarao Bondada, Daret K. St. Clair, D. Allan Butterfield

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Doxorubicin (DOX) is an anticancer drug used for the treatment of solid tumors. The ability of DOX to treat cancer is not specific to cancer cells; some of the cells that are normal may also become targets of DOX, thereby altering the normal cellular functions and eventual cell loss. DOX effects have been studied in detail in heart because of its ability to cause cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy is not completely understood. One of organs that can be affected by DOX is thymus. DOX treatment leads to degeneration of thymus; however, since thymus undergoes age-dependent degeneration, researchers have understudied the effect of DOX on thymus. In the present investigation, we studied the effects of DOX on thymus, an organ that is important for the T-cell maturation. DOX treatment led to loss of cortical cells, decrease lymphopoiesis and increased the number of Hassells corpuscles, a marker of thymus aging. Proteomics analysis led to identification of a number of thymic proteins whose expression are altered by in vivo DOX treatment. Taken together, these results are consistent with the notion that DOX-treatment leads to thymic senescence.

Original languageEnglish
Pages (from-to)6232-6241
Number of pages10
JournalJournal of Proteome Research
Issue number12
StatePublished - Dec 3 2010

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry (all)


Dive into the research topics of 'Doxorubicin-induced thymus senescence'. Together they form a unique fingerprint.

Cite this